IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Core Viewpoint - IGC Pharma, Inc. has achieved a significant enrollment milestone of 65% in its Phase 2 CALMA clinical trial for IGC-AD1, aimed at treating agitation in Alzheimer's disease, indicating strong progress towards full enrollment and completion of the trial by early 2026 [1] Company Summary - IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease using Artificial Intelligence [1] - The proprietary formulation IGC-AD1 is being evaluated in the ongoing clinical trial, which is crucial for the company's development pipeline [1] Industry Context - The advancement in clinical trials for Alzheimer's treatments is critical, given the increasing prevalence of the disease and the need for effective therapies [1]